Filing Flows

Filing Flows › 8-K events › Supernus Pharmaceuticals

Supernus Pharmaceuticals: notice of delisting or failure to meet a listing standard

Form 8-K filed Nov 2, 2026 · items 3.01

What the filing says

In connection with the consummation of the Merger on November 2, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) notified Nasdaq of the completion of the Merger and requested that Nasdaq (i) suspend trading of the Supernus Common Stock, effective prior to the opening of trading on November 2, 2026, and (ii) file w

Read the filing on SEC EDGAR →

What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →

What this kind of filing means

Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.

Supernus Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$226.8M
Revenue Y/Y+18%
Operating margin9.3%
IndustryPharmaceutical Preparations

Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%. The chart follows the revenue to costs, profit and cash.

Supernus Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Supernus Pharmaceuticals’s other material 8-Ks

Other recent delisting notices

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.